What's in Adare Pharmaceuticals, Inc.'s pipeline?

Adare Pharmaceuticals, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Adare Pharmaceuticals, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/adare-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Adare Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Adare Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
APT-1011	APT-1011	phase 3	Permeation enhancer	Intestinal tight junction proteins (claudins)	Drug delivery / Multiple therapeutic areas

Therapeutic area mix

Drug delivery / Multiple therapeutic areas · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Adare Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Adare Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adare-pharmaceuticals-inc. Accessed 2026-05-16.